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Abstract 25 
The impact of hydrodynamics and media composition on nifedipine dissolution profile from IR 26 
(immediate release) soft capsules was investigated using dissolution apparatus USP1, USP2, 27 
USP3 and USP4 (United State Pharmacopoeia). Media composition was varied in terms of pH 28 
and content, to mimic the dosage form intake with water or non-alcoholic beverages (orange 29 
juice) and alcoholic beverages (orange juice/ethanol mixture (47% v/v)). Through construction 30 
of in vitro-in vivo correlations (IVIVC) with corresponding in vivo data from the literature, it 31 
was possible to evaluate the in vitro conditions that are likely to simulate the in vivo formulation 32 
behaviour. Both linear and nonlinear correlations were obtained depending on experimental set-33 
ups. Testing of 20 mg nifedipine capsules in FaSSGFst (Fasted State Simulated Gastric Fluid 34 
pH 1.6; water administration) produced IVIVC with the USP3 (after time scaling) and USP4 35 
apparatus. IVIVC were obtained for USP2, USP3 and USP4 in FaSSGFoj (Fasted State 36 
Simulated Gastric Fluid pH 3.4; orange juice administration). Linear and nonlinear correlations 37 
were obtained with the USP1, USP2 and USP3 apparatus when testing the capsules in 38 
FaSSGFoj/EtOH (orange juice/ethanol administration). This study highlighted that selection of 39 
physiologically relevant dissolution set-ups is critical for predicting the in vivo impact of 40 
formulations co-administration with water, non-alcoholic and alcoholic beverages. 41 
 42 
Keywords: IVIVC, Biorelevant dissolution, capsule rupture time, Nifedipine, Immediate 43 
release, hydrodynamics, special dissolution media, non-alcoholic beverages, alcoholic 44 
beverages 45 
 46 
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 50 
1 Introduction 51 
Oral dosage forms are usually taken with a glass of water (Fuchs, 2009), to aid the swallowing 52 
of the formulation. But in the clinic, as well as in everyday life, other beverages can also be 53 
used to aid the swallowing of the medicament, such as fruit juices and, in more extreme cases, 54 
alcoholic beverages. While metabolic interactions with fruit juice are well known (An et al., 55 
2015; Bailey et al., 1998), the interaction between dosage forms and other type of beverages is 56 
still limited and mainly focused on tablets disintegration (Akinleye et al., 2007; Anwar et al., 57 
2005; Chuong et al., 2010; Kalantzi et al., 2005; Wells and Losin, 2008; Zuo et al., 2013).  58 
Regarding the intake of oral medications with alcoholic beverages, about ten years ago, serious 59 
concerns were raised by FDA for modified release (MR) formulations (FDA Alert for 60 
Healthcare Professionals, 2005; Meyer and Hussain, 2005). This led to the suggestion of 61 
specific experiments designed to verify, in vitro, the impact of ethanol on the dissolution profile 62 
from such formulations. These studies are requested by FDA depending on the product 63 
requiring registration (US FDA, n.d.). Consequently, extensive studies have been performed in 64 
order to investigate the interactions between MR formulations and ethanol (Jedinger et al., 65 
2015; Johnson et al., 2008; Larsson et al., 2010; Lennernäs, 2009; Palmer et al., 2011; Roberts 66 
et al., 2007; Rosiaux et al., 2014, 2013a, 2013b; Roth et al., 2009; Sathyan et al., 2008; Smith 67 
et al., 2010; Traynor et al., 2008) and to develop alcohol resistant formulations (Jedinger et al., 68 
2014; Keen et al., 2015). Recently, this interest has been extended also to immediate release 69 
(IR) formulations containing drugs with poor aqueous solubility (Fagerberg et al., 2015). It has 70 
been found that the solubility of neutral and acidic poorly soluble drugs is increased in media 71 
containing 20% v/v ethanol, compared to that in Fasted State Simulated Intestinal Fluid 72 
(FaSSIF), while bases have shown a substance specific solubility (Fagerberg et al., 2012). 73 
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Nifedipine is a calcium antagonist used clinically to treat hypertension and angina, and it is 74 
available in both IR and MR oral formulations. Nifedipine is a neutral compound classified as 75 
BCS Class II (Thelen et al., 2010), with a low solubility in water of 5 to 6 μg/mL over the pH 76 
range of 2 to 10 (Yang and de Villiers, 2004) and high permeability (Gajendran et al., 2015). 77 
Its pharmacokinetic parameters following oral dosing are dependent on the type of dosage form 78 
used (Toal, 2004). Generally, the peak plasma concentration (Cmax) of nifedipine administered 79 
orally as IR capsules appears between 0.5 and 2.2 hours post-dose, for MR tablets it ranges 80 
from 1.6 to 4.2 hours (Sorkin et al., 1985) and for GITS (Gastro-Intestinal Therapeutic System) 81 
tablets, based on an osmotic pump system, the Cmax is reached, following a lag phase of 1 to 2 82 
hours, after 8 to 10 hours (Schug et al., 2002). 83 
In the study of Qureshi and co-workers (Qureshi et al., 1992) it was observed that co-84 
administration of nifedipine IR capsules with an orange juice drink containing 47% v/v ethanol 85 
resulted in a faster onset of action and an increased bioavailability of nifedipine, compared to 86 
the administration of the same dose with orange juice only. These effects were attributed to  an 87 
increased absorption rate and a simultaneous inhibition of the metabolism of the drug due to 88 
the ethanol, as no differences in the elimination rate between nonalcoholic and alcoholic 89 
beverages were observed (Qureshi et al., 1992).  90 
Studies investigating the increased absorption of drugs when taken with alcoholic beverage 91 
raise ethical issues, due to the high risks of toxicity and side effects that can expose the subject 92 
in a life threatening situation. In this contest, generation of in silico PK profiles of a drug, using 93 
solubility measurements, can be used to predict the in vivo absorption when co-administration 94 
with alcoholic beverages occurs (Fagerberg et al., 2015). However, the extent of drug 95 
dissolution from the IR formulation may be also affected by the presence of ethanol in the 96 
stomach. Furthermore, there is limited literature available regarding the possible interactions 97 
between dosage forms and beverages other than water. Therefore, in the present study the most 98 
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commonly used dissolution apparatus (namely USP1, USP2, USP3 and USP4 apparatus) were 99 
used, and their parameters were varied in such a way that different set-ups could be investigated. 100 
The aims of this study were to investigate the impact of the variation of the dissolution 101 
parameters on the drug dissolution and to evaluate which experimental conditions better 102 
simulate the in vivo scenario of taking an IR formulation with water, orange juice and an orange 103 
juice-alcoholic mixture. Based on the in vitro dissolution data and the in vivo absorption data, 104 
level A in vitro-in vivo correlations (IVIVC) were obtained. The drug dissolution from an IR 105 
capsule is dependent on the time at which the capsule ruptures and releases its content, and this 106 
value was also calculated to support the understanding of the dissolution data as well as the 107 
impact of water and alcoholic and non-alcoholic beverages on capsule rupture time.  108 
 109 
2 Materials and Methods 110 
2.1 Materials  111 
Sodium chloride, pepsin from porcine gastric mucosa (Ph. Eur., lot BCBL9753V) and 112 
nifedipine powder (≥ 98% HPLC) were purchased from Sigma-Aldrich Chemie GmbH 113 
(Steinheim, Germany). Egg- lecithin (Lipoid E PCS, Phosphatidylcholine from egg) was from 114 
Lipoid GmbH (Ludwigshafen, Germany). Sodium taurocholate was purchased or kindly 115 
donated by Prodotti Chimici e Alimentari S.p.A (Basaluzzo, AL, Italy). Ethanol 96% Ph.Eur. 116 
was from VWR BDH Prolabo Chemicals (Leuven, Belgium). Immediate release (IR) soft 117 
gelatine capsules of nifedipine (Adalat® 10 mg, 90 soft capsules, batch n°: ITA26UU, from 118 
Bayer Pharma AG, Leverkusen, Germany) were used in the studies. Water was of Milli-Q 119 
grade. Cellulose nitrate (CN) membrane syringe filters with a pore size of 0.45 µm were from 120 
Whatman® (GE Healthcare Life Sciences, UK), while regenerated cellulose (RC) membrane 121 
syringe filters with a pore size of 0.45 µm were from (Cronus, LabHut Ltd, UK). All other 122 
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reagents and chemicals were of analytical grade and were used as received, without further 123 
purification. 124 
 125 
2.2 Dissolution media preparation 126 
Dissolution experiments were performed in Simulated Gastric Fluid without pepsin (SGFsp) 127 
pH 1.2 (United States Pharmacopeia, 2015a), Fasted State Simulated Gastric Fluid at pH 1.6 128 
(FaSSGFst) and pH 3.4 (FaSSGFoj). The FaSSGF media were freshly prepared for each 129 
experiment as described by Vertzoni et al. (Vertzoni et al., 2010), and `in the case of FaSSGFoj 130 
the pH of the buffer was adjusted with NaOH 1.0 N to obtain a pH value of 3.4. The adjustment 131 
of the FaSSGF pH from 1.6 to 3.4 was performed in order to mimic the gastric pH after 132 
administration of orange juice as in the in vivo study performed by Qureshi et al. (Qureshi et 133 
al., 1992), as  the pH of orange juice was found to be 3.4. The experiments were not directly 134 
performed in orange juice as no difference in nifedipine’s solubility was observed between 135 
FaSSGFoj and orange juice (data not shown) and therefore FaSSGFoj was chosen as the 136 
dissolution medium. The impact of orange juice components, which may affect capsule rupture 137 
time, was not taken into account in this study, as the type of orange juice used in the in vivo 138 
study was not indicated. The ethanol containing media were prepared by adding the required 139 
volume of ethanol to FaSSGFst or FaSSGFoj, in order to obtain a final ethanol concentration 140 
of 47% v/v, as the one used in the in vivo study from Qureshi et al (Qureshi et al., 1992).  141 
 142 
2.3 Dissolution experiments  143 
2.3.1 USP1 and USP2 Apparatus 144 
Dissolution experiments were performed using USP1 and USP2 apparatus (Dissolution tester 145 
DT826 LH, Automatic Sampling Station, Syringe Pump SP840, Fraction Collector FRL800, 146 
all from Erweka). Each probe of the automatic sampling station was equipped with PTFE intake 147 
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liquid-filters (10 µm, Erweka). Dissolution of 10 mg nifedipine Adalat® IR capsules was 148 
performed in the USP2 apparatus at 50 rpm, 900 mL SGFsp as described in the Nifedipine 149 
Monograph (United States Pharmacopeia, 2015b). Dissolution of 20 mg (2 x 10 mg capsules) 150 
nifedipine Adalat® IR capsules was performed in the USP2 apparatus at 50 rpm and 500 mL of 151 
SGFsp.  152 
The experimental combinations performed with the varying parameters are presented in Table 153 
1. The parameters studied were: volume of media (500 and 900 mL), rotational speed (50 and 154 
100 rpm), pH (1.6 and 3.4), and ethanol content (0 and 47% v/v). Two Adalat® 10 mg IR 155 
capsules were used for each replicate in order to mimic the in vivo study from Qureshi et al 156 
(Qureshi et al., 1992). In the case of USP2 apparatus each capsule was placed in a stainless steel 157 
sinker (Copley, UK), in order to avoid floating of the capsule in the vessel. Run time for the 158 
dissolution experiments was 2 h and the temperature was set to 37 ± 0.5 ⁰C. One mL sample 159 
was withdrawn at 5, 10, 15, 20, 25, 30, 40, 60, 90, and 120 min and collected in amber vials. 160 
All experiments were performed in triplicate. 161 
 162 
2.3.2 USP3 apparatus 163 
Variables tested for experiments with the USP3 apparatus were: volume of media (100 and 200 164 
mL), pH (1.6 and 3.4), dipping rate (5 and 15 dpm), and ethanol (0 and 47% v/v). The 165 
experimental combinations performed with the varying parameters are presented in Table 1. In 166 
the dissolution experiments (n = 3) performed with the USP3 apparatus (Bio-Dis Reciprocating 167 
Cylinder Apparatus and 750 Heater, both from Agilent Technologies) two Adalat® 10 mg 168 
capsules were inserted in the reciprocating cylinder. Run time for the dissolution experiments 169 
was 18 minutes, as preliminary experiments showed that this was the optimal time required for 170 
capturing the very fast dissolution of the capsules. The temperature was set to 37 ± 0.5°C. 171 
Samples of 5 mL were collected at 3, 6, 9, 12, 15, and 18 minutes with a glass syringe (Fortuna 172 
8 
 
Optima, Poulten & Graf GmbH, Germany) and they were filtered discarding the first 1 mL. The 173 
remaining 4 mL were used for the drug analysis. CN filters were used while performing the 174 
dissolution in medium without ethanol; whereas RC filters were used when ethanol was present 175 
in the dissolution medium.  176 
 177 
2.3.3 USP4 apparatus 178 
Variables tested for the experiments with the USP4 apparatus were: flow rate (4 and 8 mL/min), 179 
pH (1.6 and 3.4), and mode of operation (open and closed mode). Experiments with ethanol 180 
were not performed with the USP4 apparatus, due to incompatibility of the tubing of this 181 
apparatus with this solvent. The experimental combinations performed with the varying 182 
parameters are presented in Table 1. 183 
Dissolution experiments (n = 3) were performed on a USP4 apparatus - Flow-Through-cell 184 
Dissolution tester (type DFZ 720, Piston pump type HKP 720, and Heater DH 1520i, Erweka 185 
GmbH) equipped with large cells (22.6 mm diameter), a 5 mm glass bead at the bottom of the 186 
cell and small glass beads (1 mm diameter) filling the cone in the cell. In each cell, two Adalat® 187 
10 mg capsules were placed on the top of the small beads and a tablet holder was placed in the 188 
reverse position in order to avoid floating of the capsules. On top of each cell, two filters were 189 
placed, namely a GF/D filter (Glass Microfibre Filters 24 mm, Whatman™) and a GF/F filter 190 
(Glass Microfibre Filters 24 mm, Whatman™). For each set-up, the run time was set to 2 hours 191 
and the temperature was set to 37 ± 0.5 °C. When the open mode was used, fresh medium flew 192 
through the cells and the samples were collected in glass cylinders. When the closed mode was 193 
used, 900 mL of medium were placed into a Duran bottle under continuous stirring and a sample 194 
of 5 mL was withdrawn and volume replacement with fresh medium was made after each 195 
sampling. For all the experiments, sampling times were 15, 30, 45, 60, 75, 90, 105 and 120 min.  196 
 197 
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2.4 HPLC analysis 198 
Nifedipine quantification was performed with HPLC-UV (samples from USP1 and USP2 199 
apparatus experiments: Waters 2695 Separation Module and 2996 Photodiode Array Detector; 200 
samples from USP3 and USP4 apparatus experiments: Agilent 1100) using a C18 column (250 201 
X 4.6, 5μm, Kromasil, AkzoNobel, Sweden) and MeOH/H2O 60/40 v/v as mobile phase. 202 
Injection volume was 50 μL, flow rate 1 mL/min, run time 15 min, detection at 238 nm and 203 
column temperature 22°C. Standard solutions for the calibration curves were freshly prepared 204 
in duplicate in the corresponding medium in the concentration range 0.1-54 µg/mL using a 205 
stock solution of nifedipine in methanol. All the experiments and sample preparation and 206 
analysis were performed in darkness to prevent nifedipine’s photodegradation (O’Neil, 2006). 207 
 208 
2.5 Data analysis and calculations 209 
Capsules rupture times (TR) were calculated as described by Vardakou et al. (Vardakou et al., 210 
2011). Briefly, TR was calculated as the mean time between the time at which nifedipine 211 
concentration was found to be greater than 1% (𝑡(𝑐>1%)) and the time at which nifedipine 212 
concentration was found to be 1% (𝑡(𝑐=1%)) (Eq. 1):  213 
𝑇𝑅 =
𝑡(𝑐=1%) + 𝑡(𝑐>1%)
2
 (Eq.1) 
The times corresponding to 1% were obtained from interpolation of the dissolution data.  214 
In order to be able to correlate the in vivo capsule rupture time with the in vitro capsule rupture 215 
time, it is necessary to take into account the gastric emptying. This is of high importance as the 216 
presence of orange juice or ethanol may alter the gastric emptying, and therefore influence the 217 
appearance of the drug into the bloodstream. Gastric emptying data were obtained from the 218 
literature for water, orange juice and various alcoholic mixtures (Bateman and Whittingham, 219 
1982; Cooke, 1970; Kaufman and Kaye, 1979; Levitt et al., 1997; Sun et al., 1988). The in vivo 220 
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data were corrected using the method of Elashoff and co-workers (Elashoff et al., 1982), since 221 
some of the published data did not restrained the fitting through the maximum administered 222 
volume at time zero. Therefore, gastric emptying data were analyzed by fitting the volume 223 
remaining in the stomach over time with a power exponential equation (Solver tool in Excel, 224 
Office 2013, Microsoft) (Eq. 2) (Elashoff et al., 1982):  225 
𝑓 = 2
−(
𝑡
𝑡1/2
)𝛽
 
(Eq.2) 
where f is the fraction of volume in the stomach at the time t, t1/2 is the time required to empty 226 
50% of the meal (gastric emptying time half-life) and β is the shape of the curve.  227 
In vivo absorption profiles of Adalat® nifedipine IR capsules administered with water, orange 228 
juice and orange juice/ethanol mixture were obtained after deconvolution of published oral data 229 
(Qureshi et al., 1992; Rämsch and Sommer, 1983) using the Loo-Riegelman two compartment 230 
deconvolution model (Loo and Riegelman, 1968) (Eq. 3) (Excel, Office 2013, Microsoft), since 231 
nifedipine follows two compartmental kinetics (Chung et al., 1987): 232 
(
𝐴
𝑉𝑝
)
𝑡𝑛
= 𝐶𝑝𝑡𝑛 + 𝑘𝑒𝑙 ∫ 𝐶𝑝𝑑𝑡
𝑡𝑛
𝑡0
+ 𝐶𝑡𝑡𝑛 
(Eq.3) 
The pharmacokinetic (PK) constants (kel, k12 and k21) used for the Loo-Riegelman 233 
deconvolution were calculated from published in vivo nifedipine intravenous data 234 
(Kleinbloesem et al., 1984) at the dose of 0.015 mg/kg body weight via the feathering method. 235 
Point to point in vitro-in vivo correlations (IVIVC) were obtained by correlating the in vitro 236 
dissolution and the in vivo absorption data for the same time point. When necessary, in vitro 237 
and in vivo data points were calculated using the linear interpolation method. Time scaling was 238 
applied only when the in vitro dissolution was much faster than in vivo absorption, i.e. the 239 
amount dissolved in vitro reached the plateau in 20 minutes. Levy plots were used to define the 240 
time scaling parameters, and were performed when a minimum of three time points could be 241 
used. 242 
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 243 
3 Results and discussion 244 
3.1 Dissolution data 245 
3.1.1 Simulated gastric fluid USP media (SGFsp) – Simulated fasted state stomach (acidic 246 
conditions - FaSSGFst)  247 
The dissolution profile of nifedipine IR capsules under the different dissolution conditions 248 
showed to be affected by the parameters chosen for each experimental setting, as well as the 249 
type of apparatus.  250 
The dissolution of a 10 mg nifedipine IR capsule (1 x 10 mg capsule), using the conditions 251 
described for the Nifedipine Monograph (USP 2 paddle apparatus, 50 rpm and 900 mL of 252 
SGFsp) (United States Pharmacopeia, 2015b), is shown in Figure 1, along with the dissolution 253 
of 20 mg (2 x 10 mg capsules) nifedipine IR capsules at 50 rpm and 500 mL of SGFsp. In the 254 
first experiment nifedipine dissolved completely within 20 minutes, while only about 30% of 255 
the drug dissolved in the second experiment. This indicates that increasing the dose of 256 
nifedipine and reducing the volume of the medium, induces a reduction of the amount of 257 
nifedipine dissolved, due to the lack of sink conditions and limited solubility of the drug.  258 
Precipitation of nifedipine was observed in FaSSGFst, with a total % dissolved after 120 259 
minutes of ~49%, 66%, 77% and 42% for the USP1, USP2, USP3 and USP4 apparatus, 260 
respectively (Figure 2). The theoretical maximum % of nifedipine dissolved, considering a 261 
solubility of 10.5 µg/mL in FaSSGFst (Thelen et al., 2010), would correspond to 26.25% in 500 262 
mL and 47.25% in 900 mL for a 20 mg dose. These theoretical values based on solubility are 263 
in agreement with the values observed for the USP1 experiments, while for the USP2 264 
experiments the amount of nifedipine dissolved after 2 h was found to be higher and it was not 265 
affected by the volume used in the experiment (~ 55% and 65% for 500 and 900 mL, 266 
respectively). In the USP2 apparatus the rotational speed showed to impact the rate of 267 
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nifedipine’s dispersion from the capsules. At 100 rpm the dissolution of nifedipine was fast, 268 
and approximately 100% of nifedipine dissolved just after 5 minutes, and rapidly followed by 269 
precipitation. As this rapid dissolution and precipitation was not observed with the USP1 270 
apparatus, it can be suggested that the different configuration of the two dissolution apparatus 271 
has an impact on the precipitation of nifedipine from the soft gelatin capsules. The different 272 
volume used in the USP3 apparatus did not seem to greatly impact the dissolution of nifedipine, 273 
as similar results were obtained in 100 and 200 mL after 18 minutes, while it showed to be 274 
influenced by the dipping rate, with higher dipping rate (15 dpm) leading to a higher % 275 
dissolved (74.50%) than the lower dipping rate (5 dpm) (56.87% - 61.48%). Similarly, the 276 
dissolution of nifedipine in the USP4 apparatus was not affected by the volume (open or closed 277 
system) but by the flow rate used, with higher dissolution (41.88%) to be observed at the higher 278 
flow rate (8 mL/min) compared to a 24.52-25.58% dissolved at the lower flow rate (4 mL/min).  279 
 280 
3.1.2 Simulated stomach after administration of Orange Juice (FaSSGFoj) 281 
Precipitation of nifedipine was observed in FaSSGFoj with a total % dissolved after 120 282 
minutes of ~41, 66%, 77% and 55% for the USP1, USP2, USP3 and USP4 apparatus, 283 
respectively (Figure 2). In the case of the USP1 apparatus, the volume used showed an impact 284 
on the total amount of nifedipine dissolved, similarly to when FaSSGFst was used. However, 285 
the differences in amount dissolved between 500 and 900 mL FaSSGFoj were found to be 286 
slightly less pronounced (~ 30 and 41%) than in FaSSGFst. Bigger differences between the two 287 
volumes were observed for the USP2 apparatus, with values of nifedipine dissolved after 2 h of 288 
~ 30% and 65% in 500 and 900 mL, respectively. Differences in nifedipine dissolution due to 289 
the volume used were also observed for the USP3 apparatus. In this case the % of nifedipine 290 
dissolved after 18 minutes were ~ 32% and 78% in 100 and 200 mL of FaSSGFoj, respectively. 291 
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Using the closed or open mode in the USP4 apparatus did not impact significantly the % of 292 
nifedipine dissolved at the end of the 2 h (55% and 49%, respectively). 293 
 294 
3.1.3 Simulated fasted stomach after administration of Ethanol (FaSSGFst/EtOH) 295 
Dissolution of nifedipine IR capsules in the fasted acid stomach in the presence of ethanol is 296 
shown in Figure 3 for the USP1, USP2 and USP 3 apparatus. For both USP1 and USP2 297 
apparatus the % of nifedipine dissolved at the end of the 2 h dissolution was around 100%. 298 
However, differences in the rate of dissolution were observed between the two systems, as well 299 
as between the apparatus set-up. Specifically, the following were observed: i) in both apparatus 300 
the rate of dissolution was found to be faster at 100 rpm compared to 50 rpm; ii) overall the 301 
dissolution in the USP2 apparatus was faster than in the USP1 apparatus; and iii) the difference 302 
in dissolution rate at 50 and 100 rpm was larger for the USP1 apparatus compared to the USP2 303 
apparatus.  304 
For the USP3 apparatus, the dissolution of nifedipine IR capsules reached nearly 100 % for the 305 
dipping rate of 15 dpm, despite the lower volume (100 mL), compared to the experiment 306 
performed at 5 dpm (200 mL), where only around 72% of nifedipine was dissolved after 18 307 
minutes. This suggests that the dipping rate plays a role in the dissolved amount of nifedipine, 308 
and a low dipping rate may not be sufficient to optimally dissolve the capsule shell and to 309 
disperse its content. This observation was supported by the fact that the capsule shell did not 310 
dissolve completely at the end of the dissolution experiment, especially when the dipping rate 311 
of 5 dpm was used. 312 
 313 
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3.1.4 Simulated stomach after administration of Orange Juice-Ethanol mixture 314 
(FaSSGFoj/EtOH) 315 
The dissolution of nifedipine from the capsules was complete in nearly all the FaSSGFoj/EtOH 316 
experiments, (Figure 3). For the experiments performed with the USP1 apparatus, both rotation 317 
speed and pH showed to play a role in the dissolution, while the volume did not show to have 318 
any influence. The dissolution rate of nifedipine from IR capsules in FaSSGFoj/EtOH was 319 
lower than the one in FaSSGFst/EtOH. The same observations regarding the influence of 320 
rotation speed and pH can be made also for the experiments performed in the USP2 apparatus. 321 
In the USP3 apparatus, the dipping rate was not found to affect the dissolution as in the previous 322 
case (section 3.1.3). Dissolution was found to be influenced by the volume used and by the pH. 323 
These results suggest that the presence of ethanol and the pH change have a significant effect 324 
on the capsule shell dissolution, thus impacting the overall dissolution of nifedipine from IR 325 
soft gelatin capsules, and could give an insight on the in vivo impact of ethanol on the rupture 326 
of the capsule and delivery of the drug. 327 
 328 
3.2 Absorption data 329 
The % in vivo absorbed of nifedipine after administration of IR capsules under fasting 330 
conditions (at the strengths of 10 and 20 mg) as calculated from the Loo-Riegelman 331 
deconvolution of the plasma profiles are shown in Figure 4A (Rämsch and Sommer, 1983). 332 
Nifedipine’s absorption after the administration of the 10 mg dose was faster than that of the 333 
20 mg dose, as in the latter case nifedipine precipitates in the stomach (Thelen et al., 2010). The 334 
% in vivo absorbed obtained from the Loo-Riegelman deconvolution of the plasma profiles of 335 
two 10 mg nifedipine IR capsules administered with either orange juice or orange juice/ethanol 336 
(Qureshi et al., 1992) are shown in Figure 4 B. In this case, the onset of absorption occurs earlier 337 
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when the ethanolic mixture is co-administered with the drug, compared to the co-administration 338 
of the drug with the orange juice.  339 
 340 
3.3 Capsules rupture time 341 
The in vitro dissolution results (section 3.1) obtained in this study have shown that capsule 342 
rupture time TR was affected by the dissolution conditions, and in particular, it was found to be 343 
faster in the alcohol free media compared to the alcoholic mixtures (Figure 5). The capsule 344 
content dissolved after few minutes in both FaSSGFst and FaSSGFoj in the experiments 345 
performed with the USP1, USP2 and USP3 apparatus (below 7 minutes), while the capsule 346 
rupture times observed with the USP4 apparatus were higher than with the other three apparatus 347 
(ranging from ~ 8 to 23 minutes, depending on the experimental set-up). The TR was affected 348 
by the pH and the rotation speed/flow rate used, with a TR increase as the pH increased and a 349 
TR decrease as the rotation speed/flow rate increased. The pH effect was not observed in the 350 
case of the USP4 apparatus. 351 
Comparing the TR values obtained experimentally with in vivo data, it is possible to observe 352 
that the TR value obtained from the USP 4 apparatus is within the 10-15 minutes rupture time 353 
observed in vivo for standard soft gelatin capsules (Teles et al., 2014) and within the 15 min in 354 
vitro requirement from the USP General Chapter <2040> on Disintegration and Dissolution of 355 
Dietary Supplements (United States Pharmacopeia, 2015c). On the contrary, the faster rupture 356 
time observed for the other three apparatus is likely to be due to the different hydrodynamics, 357 
which may accelerate the rupture of the capsule shell compared to the in vivo conditions. In the 358 
in vivo study from Qureshi et al. (Qureshi et al., 1992), the nifedipine plasma onset was found 359 
to be faster in the presence of ethanol, and this was related to an increased absorption rate and 360 
a simultaneous inhibition of the metabolism of the drug when ethanol was co-administered 361 
(Qureshi et al., 1992). However, when comparing the TR values in FaSSGFoj obtained with all 362 
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the experimental setups with the in vivo calculated rupture time after the administration of 363 
orange juice (TR = 30.38 minutes), a lower value was observed in vitro. From the deconvoluted 364 
nifedipine plasma data in the presence of the orange juice/ethanol mixture, the TR was calculated 365 
to be 12.06 minutes and similar values were obtained from the USP1, 2 and 3 apparatus in 366 
FaSSGFoj/EtOH (between 12.72-19.48, 8.95-12.78 and 7.12-15.06 minutes, respectively).  367 
Since the in vivo TR originates from plasma deconvoluted data obtained from Qureshi et al. 368 
(Qureshi et al., 1992), the values of TR for the orange juice and the orange juice/ethanol mixture 369 
(30.38 and 12.06 minutes, respectively) can be affected by the following factors: (i) interactions 370 
occurring between the capsule shell and the beverage; (ii) gastric emptying rate of the beverage; 371 
(iii) sampling times of the study; (iv) solubilisation/precipitation of the nifedipine due to the 372 
composition and volume of the administered beverage; (v) nifedipine permeability.  373 
Interactions can occur between the capsule shell and the beverage, and it is possible that the 374 
presence of specific components in the orange juice may retard the capsule shell dissolution. 375 
The capsule rupture times calculated from the in vivo deconvoluted data from Rämsch and 376 
Sommer (Rämsch and Sommer, 1983) show that the TR for a 10 mg capsule is 8.47 minutes, 377 
while for 20 mg capsules is 12.84 minutes. Both values are within the expected in vivo times of 378 
10-15 minutes observed by Teles et al for standard soft gelatin capsules (Teles et al., 2014) . 379 
The different TR calculated from the clinical experiments with water (12.84 minutes) and orange 380 
juice (30.38 minutes) indicates the interaction between the orange juice and the capsules shell.  381 
Gastric emptying is a process regulated by the calorific content of the meal and its volume(Hunt 382 
and Stubbs, 1975). However, the impact of gastric emptying of orange juice on the in vivo TR 383 
calculation can be considered to be minimal and can be excluded by considering the gastric 384 
emptying time data of these beverages (liquid meals). The half-emptying time (t1/2) of 400 mL 385 
orange juice has been found to be in the range of 14 to 18.7 minutes, depending on the 386 
temperature (Sun et al., 1988), and of 16.37 minutes for 500 mL orange juice cordial (Bateman 387 
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and Whittingham, 1982) (a diluted orange juice drink). In comparison, a volume of 350 mL of 388 
water has shown to have a t1/2 of 9.66 minutes (Cooke, 1970). Similarly to the orange juice, the 389 
influence of the gastric emptying on the calculated in vivo TR can be excluded for the orange 390 
juice/ethanol mixture, despite the ethanol inhibitory effect on gastric emptying (Franke et al., 391 
2004). Gastric emptying time studies performed in vivo for various ethanol mixtures have 392 
shown that the value of t1/2 is affected by the volume and the ethanol content. After reanalysis 393 
of published data, a value of 11.05 minutes was calculated for 350 mL mixture of ethanol ~7% 394 
v/v (Cooke, 1970), 3.38 minutes for a 380 mL mixture containing 0.15 g/Kg ethanol 395 
(corresponding to ~ 3 to 4% v/v of ethanol) (Levitt et al., 1997), and 16.95 minutes for 750 mL 396 
mixture of ethanol 11% v/v (Kaufman and Kaye, 1979). The latter value is within the range 397 
observed by Franke et al. (Franke et al., 2004), which found that 500 mL of ethanol 10% v/v 398 
were emptied after 22.7 minutes. For higher % of ethanol the only available study is that of 399 
Franke et al (Franke et al., 2004), in which the t1/2 of 125 mL of 40% v/v ethanol mixture and 400 
125 mL of whisky 40% v/v have been found to be 27.8 and 26.4 minutes, respectively. 401 
However, in this study, the alcoholic drinks were rapidly followed by the intake of 125 mL of 402 
water, which will reduce the ethanol concentration in the stomach to about 20% v/v. The gastric 403 
emptying times for these higher ethanol concentrations indicate that the gastric emptying of the 404 
orange juice/ethanol mixture from the stomach does not affect the calculation of the in vivo TR 405 
for the nifedipine capsules.  406 
The sampling times in the study of Qureshi et al. (Qureshi et al., 1992), with the first plasma 407 
sample collected after 19.8 minutes, may affect the calculations of the TR for the orange 408 
juice/ethanol mixture, as any earlier rupture of the capsule and absorption of nifedipine was not 409 
detected. The fact that in our experimental set up FaSSGFoj was used instead of orange juice 410 
cannot exclude the possibility of interactions between the orange juice components with the 411 
capsule shell. 412 
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It is likely that solubilisation (in the case of the orange juice/ethanol mixture) or precipitation 413 
(in the case of orange juice) of nifedipine, due to the administered liquid composition and 414 
volume, can affect the appearance of the drug in the plasma, and therefore the TR. This is 415 
confirmed by the experiments performed by Thelen and coworkers (Thelen et al., 2010) in 416 
FaSSGF, for which precipitation of nifedipine was observed. Since nifedipine’s permeability is 417 
rather high (Gajendran et al., 2015), the dissolved nifedipine will be absorbed as soon as it is 418 
released into the duodenum. Also, nifedipine’s permeability is increased in the upper 419 
gastrointestinal tract due to the presence of ethanol (Lavo et al., 1992; Volpe et al., 2008). 420 
Therefore, the increased plasma onset observed in vivo could be due to the higher solubility of 421 
nifedipine in the alcoholic mixture, while the slightly lower plasma concentration observed in 422 
the presence of pure orange juice could be due to interactions between the capsules’ shell and 423 
the orange juice, and the precipitation of nifedipine in the stomach. 424 
 425 
3.4 In Vitro- In Vivo Correlations (IVIVC) 426 
The development of IVIVC was based on the correlation of the absorption data from the 427 
deconvoluted plasma concentration time profiles in water, orange juice and orange juice/ethanol 428 
mixture with the dissolution data from the experiments in FaSSGFst, FaSSGFoj and 429 
FaSSGFoj/EtOH, respectively. 430 
 431 
3.4.1 Fasted stomach (acidic conditions) 432 
For the two Pharmacopoeial experiments performed in the USP2 apparatus in SGFsp, the in 433 
vitro dissolution was found to be faster than the in vivo absorption (calculated from the plasma 434 
concentration data from Rämsch et al. (Rämsch and Sommer, 1983), Figure 4), as it is shown 435 
in Figure 6. In the case of the test performed with a 10 mg dose under the Pharmacopoeial 436 
conditions (50 rpm and 900 mL), a linear correlation was obtained between the in vitro amount 437 
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dissolved and the in vivo amount absorbed after time scaling of the in vitro data (y = 1.0707x – 438 
2.8809, R2 = 0.9733) (Figure 6). In the case of the experiment performed with a reduced 439 
volume, lower rotation speed and higher dose, the dissolution in vitro was faster than the 440 
absorption in vivo at the beginning, but then the precipitation occurring in vitro prevented any 441 
further dissolution, while in vivo absorption was observed despite the precipitation (Figure 6). 442 
In the case of the dissolution experiments performed in FaSSGFst at varying conditions, 443 
generally it was not possible to obtain any correlation with the experiments performed with the 444 
USP1, and USP2 apparatus, as the in vitro dissolution was much slower than the in vivo 445 
absorption of nifedipine administered with a glass of water (Rämsch and Sommer, 1983) 446 
(Figure 4). Only in the case of the dissolution data obtained with the USP3 apparatus at 5 dpm 447 
and with 100 mL of FaSSGFst, a linear IVIVC was obtained after time scaling of the in vitro 448 
data (y = 0.7933x + 3.9437, R2 = 0.9641), Figure 7A. The in vitro dissolution experiments 449 
performed with the USP4 apparatus resulted in two linear correlations, as shown in Figure 7B. 450 
The linear correlations were obtained for the experiment performed at 8 mL/min in the open 451 
mode (y = 2.4428x – 32.985, R2 = 0.9319), and for the experiment performed at 4 mL/min in 452 
the open mode (y = 3.6093x - 12.294, R2 = 0.9915).  453 
 454 
3.4.2 Stomach after administration of Orange Juice 455 
Time scaling of the in vitro data in FaSSGFoj was not possible for the dissolution data from the 456 
USP1 apparatus due to the fast and incomplete in vitro dissolution. The USP2 produced one 457 
linear correlation after time scaling for the experiment performed at 100 rpm and 900 mL (y = 458 
1.0254x + 9.9612, R2 = 0.9466), Figure 8A. For the dissolution data from the USP3 apparatus 459 
a linear correlation was obtained for the experiment performed at 5 dpm and 200 mL after time 460 
scaling (y = 0.8927 + 7.5831¸ R2 = 0.9503), as shown in Figure 8B. 461 
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The dissolution data from the USP4 apparatus led, after time scaling of the in vitro data, to two 462 
linear IVIVC when simulating the intake of two nifedipine capsules with orange juice, Figure 463 
8C. The in vitro dissolution data  which correlated well with the in vivo data were from the 464 
experiments performed at 4 mL/min in the open mode (y = 1.2274x – 1.944¸R2 = 0.9627) and 465 
at 8 mL/min in the closed mode (y = 1.0057 + 0.3331¸R2 = 0.9767). 466 
 467 
3.4.3 Stomach after administration of Orange Juice-Ethanol mixture 468 
In the case of the dissolution experiments performed in FaSSGFoj/EtOH simulating the orange 469 
juice/ethanol mixture, one nonlinear and two linear IVIVCs were achieved for the in vitro data 470 
from the USP1 apparatus, Figure 9A. 471 
The nonlinear correlation was obtained for the dissolution data from the experiment performed 472 
at 100 rpm and 500 mL (y = 2.788 e0.30309x ¸ R2 = 0.9908), while the other two linear 473 
correlations were obtained for the dissolution data from the experiments performed at 50 rpm 474 
and 500 mL (y = 0.7086x + 0.612¸ R2 = 0.9978) and 50 rpm and 900 mL (y = 0.7595x + 2.5778¸ 475 
R2 = 0.9813).  476 
Two time scaled linear and one non-linear correlations were obtained for the in vitro data from 477 
the USP2 apparatus, Figure 9B. The nonlinear correlation (without time scaling) was obtained 478 
for the data from the experiment performed at 50 rpm and 900 mL (y = 2.4468 e0.0356x¸ R2 = 479 
0.9972). The in vitro data that showed correlations with the in vivo data after time scaling were 480 
from the experiments performed at 50 rpm and 500 mL (y = 0.9793 + 2.8929¸ R2 = 0.9820), 481 
and 100 rpm and 500 mL (y = 1.0382 + 0.024¸ R2 = 0.9591). After time scaling, a linear 482 
correlation was obtained also for the data from the USP3 apparatus at the experimental set up 483 
of 15 dpm and 200 mL (y = 1.0327 + 3.7304¸ R2 = 0.9300). In the cases where time scaling of 484 
the data was required, in vitro dissolution was found to be faster than in vivo absorption.  485 
 486 
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4 Conclusion 487 
The in vitro dissolution studies showed that the hydrodynamics, as well as the media 488 
composition, played a key role in the establishment of good IVIVC for nifedipine’s IR 489 
formulations. With respect to the fluid dynamics, at 50 rpm the hydrodynamics in both USP1 490 
and USP2 apparatus is much higher than the in vivo hydrodynamics. The fluid velocities 491 
generally produced by the dissolution apparatus are very high and have Reynolds numbers 492 
between 5000 and 10000 (Mudie et al., 2010), while in vivo the flow is non turbulent and the 493 
Reynolds number range between 1 and 30 (Mudie et al., 2010), with maximum values between 494 
35 and 100-125 when considering spikes due to high flow (Diebold, 2005). At 50 rpm the USP2 495 
apparatus produces maximum velocities between 0.049 and 0.067 m/s (D’Arcy et al., 2005), 496 
while the USP1 apparatus has shown to have maximum velocities generally lower than the 497 
USP2 apparatus at the same rotational speed and with a maximum value of 0.026 m/s (D’Arcy 498 
et al., 2009). The calculated velocities in the stomach due to retropulsive jets has been calculated 499 
to be around 0.0075 m/s (Pal et al., 2004), while the average transit time in the intestine ranges 500 
between 0.0002 and 0.0008 m/s (Diebold, 2005). So even at 50 rpm, the velocities experienced 501 
by the formulation in vitro are much higher than those in vivo, which is reflected by the observed 502 
IVIVCs. The hydrodynamics of the USP3 apparatus has been found to be influenced by the dip 503 
rate, with maximum velocities ranging between approximately 0.04 and 0.08 m/s for 5 and 10 504 
dpm, respectively, and showed to have a Reynold number of 1870 (corresponding to a laminar 505 
flow) (Perivilli et al., 2015). Similarly to the case of the USP1 and USP2 apparatus, fluid 506 
velocity in the USP3 apparatus is much higher than that calculated in vivo (0.0002-0.0008 m/s 507 
(Diebold, 2005)). 508 
The USP4 apparatus produces low Reynold numbers at flow rates between 4 and 50 mL/min, 509 
and the fluid velocities have been found to be, at 8 mL/min, between 0.0012 and 0.0014 m/s 510 
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(D’Arcy et al., 2011), which are closer to the in vivo values (0.0002-0.0008 m/s (Diebold, 511 
2005)).   512 
Regarding the impact of water, alcoholic and non-alcoholic beverages intake with a 513 
formulation, based on our study, when nifedipine capsules are administered with water at the 514 
dose of 10 mg, a good IVIVC was obtained with the standard dissolution set up required by the 515 
Pharmacopeia. The experiments in FaSSGFst using the four apparatus showed that no 516 
correlation could be obtained for the USP1 and USP2 apparatus, due to the fast precipitation of 517 
the administered 20 mg nifedipine capsules. For the USP3 an IVIVC was possible after time 518 
scaling of the in vitro data, due to the faster and incomplete dissolution in vitro compared to the 519 
in vivo absorption. For the USP4 apparatus the in vitro dissolution was found to be slower than 520 
the in vivo absorption.  521 
Similarly to the FaSSGFst experiment, when 20 mg nifedipine capsules were tested in the media 522 
simulating the orange juice beverage (FaSSGFoj) correlations between in vitro data and in vivo 523 
data were obtained for the USP2, USP3 and USP4 apparatus. In all cases time scaling of the 524 
data was required to obtain IVIVC, due to the faster in vitro dissolution compared to the in vivo 525 
absorption. Mimicking the co-administration of orange juice/ethanol mixture showed that all 526 
three apparatus USP1, USP2 and USP3 were able to provide good IVIVC. Interestingly, the 527 
same experimental set ups for USP1 and USP2 generated the IVIVC, even though time scaling 528 
was required for two of the experimental set ups with the USP2 apparatus, while no time scaling 529 
was necessary for the USP1. 530 
The co-administration of ethanol with nifedipine in vivo was found to impact the PK of the drug 531 
in terms of onset of action and increased bioavailability, due to faster absorption rate and 532 
metabolism inhibition (Qureshi et al., 1992). In our study, we observed that the faster absorption 533 
rate in the presence of ethanol, compared to the alcohol free water and orange juice, could be 534 
explained by several factors. The increased solubility of nifedipine in the presence of ethanol 535 
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47% v/v prevented precipitation of the drug, regardless of the liquid volume. Also, the presence 536 
of ethanol counteracted the effect of orange juice on the capsule rupture time. These two effects 537 
observed in vitro could contribute to the observed in vivo behaviour of the formulation.  538 
Choosing the appropriate in vitro dissolution conditions in terms of media and hydrodynamics 539 
is critical in order to achieve a good correlation with in vivo data. The choice of a 540 
physiologically relevant dissolution set up is critical for investigating the formulation sensitivity 541 
to various beverages, and especially those containing ethanol, so that the risk associated with 542 
its co-administration can be predicted.  543 
 544 
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Table 1 Parameters used for the dissolution experiments in USP1, USP2, USP3 and USP4 apparatus. FaSSGFst = Fasted State 730 
Simulated Gastric Fluid at the standard pH of 1.6; FaSSGFoj = Fasted State Simulated Gastric Fluid at the pH of 3.4 as for 731 
orange juice; EtOH = ethanol; SGFsp = Simulated Gastric Fluid without pepsin. 732 
Apparatus 
type 
Exp 
n° 
System 
Type 
Media type 
Rotational 
speed 
(rpm) 
Dipping 
rate 
(dpm) 
Flow rate 
(mL/min) 
Volume 
(mL) 
pH 
Ethanol 
content 
(% v/v) 
U
S
P
 1
 
1 - FaSSGFoj 50 - - 500 3.4 0 
2 - FaSSGFst 100 - - 500 1.6 0 
3 - FaSSGFst 50 - - 900 1.6 0 
4 - FaSSGFoj 100 - - 900 3.4 0 
5 - FaSSGFst/EtOH 50 - - 500 1.6 47 
6 - FaSSGFoj/EtOH 50 - - 500 3.4 47 
7 - FaSSGFoj/EtOH 100 - - 500 3.4 47 
8 - FaSSGFoj/EtOH 50 - - 900 3.4 47 
9 - FaSSGFst/EtOH 100 - - 900 1.6 47 
U
S
P
 2
 
10 - SGFsp 50 - - 900 1.2 0 
11 - SGFsp 50 - - 500 1.2 0 
12 - FaSSGFoj 50 - - 500 3.4 0 
13 - FaSSGFst 100 - - 500 1.6 0 
14 - FaSSGFst 50 - - 900 1.6 0 
15 - FaSSGFoj 100 - - 900 3.4 0 
16 - FaSSGFst/EtOH 50 - - 500 1.6 47 
17 - FaSSGFoj/EtOH 50 - - 500 3.4 47 
18 - FaSSGFoj/EtOH 100 - - 500 3.4 47 
19 - FaSSGFoj/EtOH 50 - - 900 3.4 47 
20 - FaSSGFst/EtOH 100 - - 900 1.6 47 
U
S
P
 3
 
21 - FaSSGFst - 5 - 200 1.6 0 
22 - FaSSGFst - 5 - 100 1.6 0 
23 - FaSSGFoj - 15 - 100 3.4 0 
24 - FaSSGFoj - 5 - 200 3.4 0 
25 - FaSSGFst - 15 - 200 1.6 0 
26 - FaSSGFoj/EtOH - 5 - 100 3.4 47 
27 - FaSSGFst/EtOH - 15 - 100 1.6 47 
28 - FaSSGFst/EtOH - 5 - 200 1.6 47 
29 - FaSSGFoj/EtOH - 15 - 200 3.4 47 
U
S
P
 4
 
30 Open FaSSGFoj - - 4 - 3.4 0 
31 Closed FaSSGFst - - 4 - 1.6 0 
32 Open FaSSGFst - - 8 - 1.6 0 
33 Closed FaSSGFoj - - 8 - 3.4 0 
34 Open FaSSGFst - - 4 - 1.6 0 
 733 
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Figure captions 735 
Figure 1 Dissolution profiles (n = 3) of nifedipine IR capsules: () 1 capsule of 10 mg in 900 736 
mL of SGFsp at 50 rpm and () 2 capsules of 10 mg in 500 mL of SGFsp at 50 rpm. Bars 737 
represent standard deviation. SGFsp = Simulated Gastric Fluid without pepsin. 738 
Figure 2 Dissolution profiles (n = 3) of nifedipine IR (2 x 10 mg) capsules in FaSSGF at varying 739 
dissolution conditions using USP1, USP2, USP3 and USP4 apparatus. FaSSGFst = Fasted State 740 
Simulated Gastric Fluid pH 1.6; FaSSGFoj = Fasted State Gastric Fluid pH 3.4. 741 
Figure 3 Dissolution profiles (n = 3) of nifedipine IR (2 x 10 mg) capsules in FaSSGFst/EtOH 742 
and FaSSGFoj/EtOH at varying dissolution conditions using USP1, USP2, and USP3 743 
apparatus. FaSSGFst = Fasted State Simulated Gastric Fluid pH 1.6; FaSSGFoj = Fasted State 744 
Gastric Fluid pH 3.4; EtOH = Ethanol. 745 
Figure 4 A) % of nifedipine absorbed in vivo obtained from the deconvolution of the plasma 746 
data of nifedipine capsules administered as () 20 mg and () 10 mg (Rämsch and Sommer, 747 
1983); B) % of nifedipine absorbed in vivo obtained from the deconvolution of the plasma data 748 
of nifedipine capsules administered with  orange juice () or a mixture of orange juice and 749 
ethanol () (Qureshi et al., 1992). Loo-Riegelman two compartment model was used for the 750 
deconvolution of the in vivo data. 751 
Figure 5 Mean capsule rupture times (TR) of nifedipine IR capsules in FaSSGFst, FaSSGFoj, 752 
FaSSGFst/EtOH and FaSSGFoj/EtOH obtained with the four dissolution apparatus. Bars 753 
represent the standard deviation (n = 3). 754 
Figure 6 IVIVC for in vitro data from USP2 apparatus experiments simulating the intake of 755 
nifedipine capsules with water and performed in SGFsp pH 1.2: () 10 mg in 900 mL at 50 756 
rpm (after time scaling); () 2 x 10 mg in 500 mL at 50 rpm. In vivo amount absorbed were 757 
31 
 
obtained from the deconvolution of the in vivo plasma profiles of 10 and 20 mg nifedipine 758 
capsules published by Rämsch and coworkers (Rämsch and Sommer, 1983).  759 
Figure 7 IVIVC for in vitro data from A) USP3 (after time scaling) and B) USP4 apparatus 760 
experiments simulating the intake of nifedipine capsules with water and performed in FaSSGFst 761 
(pH 1.6). In vivo amounts absorbed were obtained from the deconvolution of the in vivo plasma 762 
profiles of 20 mg nifedipine capsules published by Rämsch and coworkers (Rämsch and 763 
Sommer, 1983). 764 
 765 
Figure 8 IVIVC for in vitro data from A) USP2, B) USP3 and C) USP4 apparatus experiments 766 
simulating the intake of nifedipine capsules with orange juice in FaSSGFoj (pH 3.4). In vivo 767 
amount absorbed were obtained from the deconvolution of the in vivo plasma profiles of 20 mg 768 
nifedipine capsules published by Qureshi and coworkers (Qureshi et al., 1992). Time scaling 769 
was applied in all cases. 770 
Figure 9 IVIVC for in vitro data from A) USP1, B) USP2 and C) USP3 (after time scaling) 771 
apparatus experiments simulating the intake of nifedipine capsules with orange juice/ethanol 772 
mixture in FaSSGFoj/EtOH (pH 3.4). In vivo amount absorbed were obtained from the 773 
deconvolution of the in vivo plasma profiles of 20 mg nifedipine capsules published by Qureshi 774 
and coworkers (Qureshi et al., 1992). 775 
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